Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep Limited Announces Recruitment of Patients Completed for Part B of TACTI-002

08/31/2021 | 08:07pm EDT

Immutep Limited announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2nd line PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC) patients into the trial. Immutep expects to report further data from TACTI-002 at a scientific conference in calendar year 2021 or early calendar year 2022. Patient recruitment is now complete for Parts B and C of TACTI-002 and continues to progress well for the expansion stage of Part A. A total of 154 patients out of up to 183 are now participating in TACTI- 002 at currently 19 clinical sites across Australia, Europe, the UK and US. The data presented for 2nd line PD-1/PD-L1 resistant NSCLC at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting as part of a late breaker poster looked encouraging, especially when compared to alternative treatment options. Based on the data, the DMC confirmed a positive risk-benefit-ratio in this very difficult to treat patient population with confirmed progression (i.e. two consecutive scans) and often low PD-L1 expression levels and recommended the opening of Stage 2 of this part in March 2021.


ę S&P Capital IQ 2021
All news about IMMUTEP LIMITED
10/13IMMUTEP : Corporate Connect - A Truly Undervalued Company
PU
10/12IMMUTEP : 2021 Annual General Meeting and Key Dates
PU
10/04IMMUTEP : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During M..
MT
10/03IMMUTEP : to present Phase II TACTI-002 data at SITC 2021
PU
10/01IMMUTEP : to Present Phase II TACTI-002 Data at SITC 2021
AQ
09/29IMMUTEP : Receives $2.49 Million as R&D Tax Incentive from French Government
MT
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government
AQ
09/29IMMUTEP : Receives A$3.4 million R&D Tax Incentive from French Government (Form 6-K)
PU
09/28IMMUTEP : Receives $2.5 Million Tax Incentive from France
MT
09/28IMMUTEP : Receives A$3.4 million R&D French Tax Incentive
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 2,38 M 1,79 M 1,79 M
Net income 2022 -38,8 M -29,2 M -29,2 M
Net cash 2022 81,6 M 61,4 M 61,4 M
P/E ratio 2022 -10,5x
Yield 2022 -
Capitalization 532 M 399 M 400 M
EV / Sales 2022 189x
EV / Sales 2023 24,7x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,63 AUD
Average target price 1,18 AUD
Spread / Average Target 88,6%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
FrÚdÚric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED50.60%399
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036